鼻窦黏膜黑色素瘤患者的复发模式:一项多机构研究
该多机构回顾性研究纳入1991至2022年七家美国机构的196例鼻窦黏膜黑色素瘤患者,评估复发模式及复发后生存。复发146例(74.5%),孤立远处复发最常见(42.8%);远处复发中仅免疫治疗与12个月复发后生存改善相关(HR=0.32,95%CI=0.11-0.92,p=0.034)。
要点
- 196例中146例(74.5%)复发,孤立远处复发最常见(42.8%)
- 颈部原发治疗与未治疗相比60个月无病生存无差异(p>0.05)
- 远处复发中免疫治疗与12个月复发后生存改善相关(HR=0.32,p=0.034)
核心结论
- 鼻窦黏膜黑色素瘤复发率高、生存差;颈部原发治疗未与复发减少相关;远处复发的免疫治疗与12个月复发后生存改善相关。
研究设计与样本
- 多机构回顾性研究,纳入七家美国机构1991至2022年的196例鼻窦黏膜黑色素瘤患者。
主要发现
- 196例中146例复发(74.5%),孤立远处复发最常见(42.8%),其次为局部(28.3%)、多灶(20.7%)和区域复发(8.3%)。
- 所有患者60个月无病生存率为15.5%(标准误2.9%),60个月总生存率为44.7%(标准误3.7%)。
- 诊断时平均年龄±标准差为69.7±12.5岁,女性占54.6%。
- 26例接受颈部原发治疗的患者中,60个月无病生存与未治疗者无差异(p>0.05)。
- 颈部区域复发患者中,挽救性颈清扫或放疗未带来60个月复发后生存获益(p>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate recurrence patterns and survival after recurrence among patients with sinonasal mucosal melanoma (SNMM). METHODS: This was a multi-institutional retrospective review from seven U.S. institutions of patients with SNMM from 1991 to 2022. Recurrence was categorized as local, regional, distant, or multifocal. Kaplan-Meier tests were used to evaluate disease-free survival (DFS), overall survival (OS), and post-recurrence survival (PRS) reported with standard errors (SE) and log-rank testing used for comparison. Cox-regression was further used, with hazard ratios (HR) and 95% confidence intervals (CI) reported. RESULTS: Among 196 patients with SNMM, there were 146 patients with recurrence (74.5%). Among all patients, 60-month DFS (SE) was 15.5% (2.9%), 60-month OS (SE) was 44.7% (3.7%), mean age ± standard deviation at diagnosis was 69.7 ± 12.5 years, and 54.6% were female. In 26 patients who underwent primary treatment of the neck, 60-month DFS did not differ from no treatment (p > 0.05). Isolated distant recurrence was most common (42.8%), followed by local (28.3%), multifocal (20.7%), and regional recurrence (8.3%). Among patients with regional recurrence in the neck, there was no 60-month PRS benefit for patients undergoing salvage neck dissection or radiation (p > 0.05). Among patients with distant recurrence, only immunotherapy was associated with improved 12-month PRS (HR = 0.32, 95% CI = 0.11-0.92, p = 0.034), and no treatment group was associated with improved 24- or 60-month PRS (p > 0.05). CONCLUSION: SNMM is associated with a high recurrence rate and poor survival. Primary treatment of the neck was not associated with reduced recurrence, and immunotherapy for treatment of distant recurrence was associated with increased 12-month PRS.
引用
- Pandrangi VC, Mace JC, Abiri A, et al. Recurrence patterns among patients with sinonasal mucosal melanoma: A multi-institutional study. Int Forum Allergy Rhinol. 2023. PMID: 37265013. doi:10.1002/alr.23204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。